. While these names have been often cited as top picks in the pharmaceutical industry, are there hidden gems to look out for or do Eli Lilly and Novo Nordisk remain at the top of the class?"I think for me, Novo and Lilly are still going to be the top two.
I mean, investors are always looking at the health care space for the the next major breakthrough or scientific advancement. And we're gonna have data on that um roughly a year from now, maybe a little bit later than a year from now. Well, yeah, I mean, I think for me, Novo and Lily are still gonna be the top two, you know, as long as they're dominating in, in this kind of section of the market, um it's really tough to, you know, not ride these a little bit longer.
Not precisely sure when, but they're looking at, you know, the use of the weight loss drug on a monthly basis that's versus Lilian Novo um weekly.I mean, I've been pretty bullish on Merck all year given valuation, given the fact that they seem to be doing a lot of smart things from a business development standpoint to kind of dilute the effect of Kruta losing patent exclusivity closer to 2030.
پاکستان تازہ ترین خبریں, پاکستان عنوانات
Similar News:آپ اس سے ملتی جلتی خبریں بھی پڑھ سکتے ہیں جو ہم نے دوسرے خبروں کے ذرائع سے جمع کی ہیں۔
ذریعہ: YahooFinanceCA - 🏆 47. / 63 مزید پڑھ »